Artu Biologicals Report issue

For profit Phase 3
Founded: Lelystad Netherlands (1984)
Status: Acquired by ALK-Abello, S.A. (2010)

Organization Overview

First Clinical Trial
2006
NCT00567346
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Artu-Biologicals Europe B.V., the Netherlands

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Conjunctivitis (Phase 3)

Conjunctivitis, Allergic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2